Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.71
(
-0.17%
)
Bitcoin
66,398.85
(
0.12%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Mufaso post# 249499

Thursday, 11/02/2023 7:02:49 PM

Thursday, November 02, 2023 7:02:49 PM

Post# of 257302
TERN begins phase-1 for oral GLP-1 drug:

https://www.globenewswire.com/news-release/2023/11/02/2772813/0/en/Terns-Pharmaceuticals-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-of-TERN-601-Oral-GLP-1-Receptor-Agonist-for-Treatment-of-Obesity.html

TERN-601 is a small-molecule GLP-1 receptor agonist; because it’s not a peptide, it presumably will not have the strict fasting requirements of NVO’s oral semaglutide, Rybelsus.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today